nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—SLC22A2—Cladribine—multiple sclerosis	0.176	0.332	CbGbCtD
Amantadine—SLC22A1—Cladribine—multiple sclerosis	0.153	0.288	CbGbCtD
Amantadine—ABCB1—Methylprednisolone—multiple sclerosis	0.0469	0.0882	CbGbCtD
Amantadine—ABCB1—Mitoxantrone—multiple sclerosis	0.0342	0.0644	CbGbCtD
Amantadine—ABCB1—Betamethasone—multiple sclerosis	0.0305	0.0574	CbGbCtD
Amantadine—ABCB1—Prednisolone—multiple sclerosis	0.0301	0.0566	CbGbCtD
Amantadine—ABCB1—Prednisone—multiple sclerosis	0.0284	0.0535	CbGbCtD
Amantadine—ABCB1—Dexamethasone—multiple sclerosis	0.0177	0.0334	CbGbCtD
Amantadine—ABCB1—Methotrexate—multiple sclerosis	0.0142	0.0268	CbGbCtD
Amantadine—GRIN2C—nerve—multiple sclerosis	0.0106	0.0643	CbGeAlD
Amantadine—DDC—pineal body—multiple sclerosis	0.00946	0.0572	CbGeAlD
Amantadine—GRIN2B—nerve—multiple sclerosis	0.00841	0.0509	CbGeAlD
Amantadine—GRIN2A—nerve—multiple sclerosis	0.00735	0.0445	CbGeAlD
Amantadine—DDC—nerve—multiple sclerosis	0.00687	0.0415	CbGeAlD
Amantadine—GRIN2C—brainstem—multiple sclerosis	0.00457	0.0276	CbGeAlD
Amantadine—GRIN2D—brainstem—multiple sclerosis	0.00425	0.0257	CbGeAlD
Amantadine—GRIN1—brainstem—multiple sclerosis	0.00379	0.0229	CbGeAlD
Amantadine—GRIN2B—brainstem—multiple sclerosis	0.00361	0.0218	CbGeAlD
Amantadine—MAOB—nerve—multiple sclerosis	0.00353	0.0214	CbGeAlD
Amantadine—GRIN2C—medulla oblongata—multiple sclerosis	0.00319	0.0193	CbGeAlD
Amantadine—GRIN2A—brainstem—multiple sclerosis	0.00316	0.0191	CbGeAlD
Amantadine—DRD2—nerve—multiple sclerosis	0.00298	0.018	CbGeAlD
Amantadine—GRIN2D—medulla oblongata—multiple sclerosis	0.00296	0.0179	CbGeAlD
Amantadine—DDC—brainstem—multiple sclerosis	0.00295	0.0178	CbGeAlD
Amantadine—GRIN2D—spinal cord—multiple sclerosis	0.00264	0.016	CbGeAlD
Amantadine—GRIN1—midbrain—multiple sclerosis	0.00241	0.0146	CbGeAlD
Amantadine—GRIN2C—nervous system—multiple sclerosis	0.00239	0.0145	CbGeAlD
Amantadine—GRIN1—spinal cord—multiple sclerosis	0.00235	0.0142	CbGeAlD
Amantadine—GRIN2C—central nervous system—multiple sclerosis	0.0023	0.0139	CbGeAlD
Amantadine—GRIN2C—cerebellum—multiple sclerosis	0.00225	0.0136	CbGeAlD
Amantadine—GRIN2B—spinal cord—multiple sclerosis	0.00225	0.0136	CbGeAlD
Amantadine—GRIN2D—nervous system—multiple sclerosis	0.00223	0.0135	CbGeAlD
Amantadine—GRIN2A—medulla oblongata—multiple sclerosis	0.0022	0.0133	CbGeAlD
Amantadine—GRIN2D—central nervous system—multiple sclerosis	0.00214	0.013	CbGeAlD
Amantadine—GRIN2D—cerebellum—multiple sclerosis	0.00209	0.0127	CbGeAlD
Amantadine—GRIN3A—nervous system—multiple sclerosis	0.00209	0.0126	CbGeAlD
Amantadine—GRIN3A—central nervous system—multiple sclerosis	0.00201	0.0122	CbGeAlD
Amantadine—GRIN2A—midbrain—multiple sclerosis	0.00201	0.0122	CbGeAlD
Amantadine—GRIN1—nervous system—multiple sclerosis	0.00198	0.012	CbGeAlD
Amantadine—GRIN2A—spinal cord—multiple sclerosis	0.00196	0.0119	CbGeAlD
Amantadine—GRIN1—central nervous system—multiple sclerosis	0.00191	0.0115	CbGeAlD
Amantadine—GRIN2B—nervous system—multiple sclerosis	0.00189	0.0114	CbGeAlD
Amantadine—DDC—midbrain—multiple sclerosis	0.00188	0.0114	CbGeAlD
Amantadine—GRIN1—cerebellum—multiple sclerosis	0.00187	0.0113	CbGeAlD
Amantadine—GRIN2C—brain—multiple sclerosis	0.00183	0.0111	CbGeAlD
Amantadine—GRIN2B—central nervous system—multiple sclerosis	0.00182	0.011	CbGeAlD
Amantadine—GRIN2B—cerebellum—multiple sclerosis	0.00178	0.0108	CbGeAlD
Amantadine—GRIN2D—brain—multiple sclerosis	0.0017	0.0103	CbGeAlD
Amantadine—GRIN2A—nervous system—multiple sclerosis	0.00165	0.01	CbGeAlD
Amantadine—GRIN3A—brain—multiple sclerosis	0.0016	0.00967	CbGeAlD
Amantadine—GRIN2A—central nervous system—multiple sclerosis	0.00159	0.00963	CbGeAlD
Amantadine—GRIN2A—cerebellum—multiple sclerosis	0.00156	0.00941	CbGeAlD
Amantadine—DDC—nervous system—multiple sclerosis	0.00155	0.00934	CbGeAlD
Amantadine—MAOB—brainstem—multiple sclerosis	0.00152	0.00917	CbGeAlD
Amantadine—GRIN1—brain—multiple sclerosis	0.00152	0.00916	CbGeAlD
Amantadine—DDC—central nervous system—multiple sclerosis	0.00149	0.00899	CbGeAlD
Amantadine—GRIN2B—brain—multiple sclerosis	0.00145	0.00874	CbGeAlD
Amantadine—DRD2—brainstem—multiple sclerosis	0.00128	0.00774	CbGeAlD
Amantadine—GRIN2A—brain—multiple sclerosis	0.00126	0.00764	CbGeAlD
Amantadine—DRD2—retina—multiple sclerosis	0.00124	0.00747	CbGeAlD
Amantadine—DDC—brain—multiple sclerosis	0.00118	0.00714	CbGeAlD
Amantadine—SIGMAR1—medulla oblongata—multiple sclerosis	0.00111	0.00668	CbGeAlD
Amantadine—MAOB—medulla oblongata—multiple sclerosis	0.00106	0.0064	CbGeAlD
Amantadine—SIGMAR1—midbrain—multiple sclerosis	0.00101	0.00611	CbGeAlD
Amantadine—SIGMAR1—spinal cord—multiple sclerosis	0.000986	0.00596	CbGeAlD
Amantadine—MAOB—midbrain—multiple sclerosis	0.000967	0.00585	CbGeAlD
Amantadine—MAOB—spinal cord—multiple sclerosis	0.000943	0.0057	CbGeAlD
Amantadine—SLC22A1—nervous system—multiple sclerosis	0.000899	0.00543	CbGeAlD
Amantadine—SLC22A1—central nervous system—multiple sclerosis	0.000865	0.00523	CbGeAlD
Amantadine—DRD2—midbrain—multiple sclerosis	0.000816	0.00493	CbGeAlD
Amantadine—MAOB—nervous system—multiple sclerosis	0.000795	0.00481	CbGeAlD
Amantadine—SIGMAR1—cerebellum—multiple sclerosis	0.000781	0.00472	CbGeAlD
Amantadine—MAOB—central nervous system—multiple sclerosis	0.000765	0.00463	CbGeAlD
Amantadine—MAOB—cerebellum—multiple sclerosis	0.000748	0.00452	CbGeAlD
Amantadine—SLC22A1—brain—multiple sclerosis	0.000687	0.00415	CbGeAlD
Amantadine—DRD2—nervous system—multiple sclerosis	0.000671	0.00406	CbGeAlD
Amantadine—DRD2—central nervous system—multiple sclerosis	0.000646	0.0039	CbGeAlD
Amantadine—SIGMAR1—brain—multiple sclerosis	0.000635	0.00384	CbGeAlD
Amantadine—DRD2—cerebellum—multiple sclerosis	0.000631	0.00382	CbGeAlD
Amantadine—MAOB—brain—multiple sclerosis	0.000608	0.00367	CbGeAlD
Amantadine—ABCB1—retina—multiple sclerosis	0.000534	0.00323	CbGeAlD
Amantadine—DRD2—brain—multiple sclerosis	0.000513	0.0031	CbGeAlD
Amantadine—ABCB1—medulla oblongata—multiple sclerosis	0.000386	0.00233	CbGeAlD
Amantadine—Hallucination—Dexamethasone—multiple sclerosis	0.000374	0.0017	CcSEcCtD
Amantadine—Hallucination—Betamethasone—multiple sclerosis	0.000374	0.0017	CcSEcCtD
Amantadine—Dermatitis—Cladribine—multiple sclerosis	0.000374	0.0017	CcSEcCtD
Amantadine—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000373	0.00169	CcSEcCtD
Amantadine—Anorexia—Mitoxantrone—multiple sclerosis	0.000372	0.00169	CcSEcCtD
Amantadine—Ataxia—Methotrexate—multiple sclerosis	0.000372	0.00169	CcSEcCtD
Amantadine—Headache—Cladribine—multiple sclerosis	0.000372	0.00169	CcSEcCtD
Amantadine—Arrhythmia—Triamcinolone—multiple sclerosis	0.000371	0.00168	CcSEcCtD
Amantadine—Vision blurred—Prednisolone—multiple sclerosis	0.00037	0.00168	CcSEcCtD
Amantadine—Arrhythmia—Methylprednisolone—multiple sclerosis	0.00037	0.00168	CcSEcCtD
Amantadine—Liver function test abnormal—Methotrexate—multiple sclerosis	0.000366	0.00166	CcSEcCtD
Amantadine—Hypotension—Mitoxantrone—multiple sclerosis	0.000365	0.00166	CcSEcCtD
Amantadine—Visual impairment—Betamethasone—multiple sclerosis	0.000363	0.00164	CcSEcCtD
Amantadine—Visual impairment—Dexamethasone—multiple sclerosis	0.000363	0.00164	CcSEcCtD
Amantadine—Mental disorder—Methylprednisolone—multiple sclerosis	0.000363	0.00164	CcSEcCtD
Amantadine—Malnutrition—Methylprednisolone—multiple sclerosis	0.00036	0.00163	CcSEcCtD
Amantadine—Hypersensitivity—Azathioprine—multiple sclerosis	0.000356	0.00161	CcSEcCtD
Amantadine—Nausea—Cladribine—multiple sclerosis	0.000353	0.0016	CcSEcCtD
Amantadine—ABCB1—midbrain—multiple sclerosis	0.000353	0.00213	CbGeAlD
Amantadine—Eye disorder—Dexamethasone—multiple sclerosis	0.000352	0.0016	CcSEcCtD
Amantadine—Eye disorder—Betamethasone—multiple sclerosis	0.000352	0.0016	CcSEcCtD
Amantadine—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000351	0.00159	CcSEcCtD
Amantadine—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000348	0.00158	CcSEcCtD
Amantadine—Somnolence—Mitoxantrone—multiple sclerosis	0.000347	0.00157	CcSEcCtD
Amantadine—ABCB1—spinal cord—multiple sclerosis	0.000344	0.00208	CbGeAlD
Amantadine—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000344	0.00156	CcSEcCtD
Amantadine—Angiopathy—Betamethasone—multiple sclerosis	0.000341	0.00155	CcSEcCtD
Amantadine—Angiopathy—Dexamethasone—multiple sclerosis	0.000341	0.00155	CcSEcCtD
Amantadine—Convulsion—Prednisolone—multiple sclerosis	0.00034	0.00154	CcSEcCtD
Amantadine—Decreased appetite—Mitoxantrone—multiple sclerosis	0.00034	0.00154	CcSEcCtD
Amantadine—Hypertension—Prednisolone—multiple sclerosis	0.000339	0.00154	CcSEcCtD
Amantadine—Fatigue—Mitoxantrone—multiple sclerosis	0.000337	0.00153	CcSEcCtD
Amantadine—Arrhythmia—Betamethasone—multiple sclerosis	0.000336	0.00152	CcSEcCtD
Amantadine—Arrhythmia—Dexamethasone—multiple sclerosis	0.000336	0.00152	CcSEcCtD
Amantadine—Constipation—Mitoxantrone—multiple sclerosis	0.000334	0.00151	CcSEcCtD
Amantadine—Alopecia—Dexamethasone—multiple sclerosis	0.000333	0.00151	CcSEcCtD
Amantadine—Alopecia—Betamethasone—multiple sclerosis	0.000333	0.00151	CcSEcCtD
Amantadine—Diarrhoea—Azathioprine—multiple sclerosis	0.000331	0.0015	CcSEcCtD
Amantadine—Hallucination—Prednisone—multiple sclerosis	0.000326	0.00148	CcSEcCtD
Amantadine—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000322	0.00146	CcSEcCtD
Amantadine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.00032	0.00145	CcSEcCtD
Amantadine—Oedema—Prednisolone—multiple sclerosis	0.00032	0.00145	CcSEcCtD
Amantadine—Neutropenia—Methotrexate—multiple sclerosis	0.00032	0.00145	CcSEcCtD
Amantadine—Dizziness—Azathioprine—multiple sclerosis	0.00032	0.00145	CcSEcCtD
Amantadine—Convulsion—Triamcinolone—multiple sclerosis	0.000313	0.00142	CcSEcCtD
Amantadine—Tachycardia—Prednisolone—multiple sclerosis	0.000313	0.00142	CcSEcCtD
Amantadine—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000312	0.00142	CcSEcCtD
Amantadine—Convulsion—Methylprednisolone—multiple sclerosis	0.000312	0.00142	CcSEcCtD
Amantadine—Hypertension—Triamcinolone—multiple sclerosis	0.000312	0.00141	CcSEcCtD
Amantadine—Hypertension—Methylprednisolone—multiple sclerosis	0.000311	0.00141	CcSEcCtD
Amantadine—Hyperhidrosis—Prednisolone—multiple sclerosis	0.00031	0.00141	CcSEcCtD
Amantadine—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000309	0.0014	CcSEcCtD
Amantadine—Vomiting—Azathioprine—multiple sclerosis	0.000307	0.00139	CcSEcCtD
Amantadine—Eye disorder—Prednisone—multiple sclerosis	0.000306	0.00139	CcSEcCtD
Amantadine—Anxiety—Methylprednisolone—multiple sclerosis	0.000306	0.00139	CcSEcCtD
Amantadine—Rash—Azathioprine—multiple sclerosis	0.000305	0.00138	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000305	0.00138	CcSEcCtD
Amantadine—Dermatitis—Azathioprine—multiple sclerosis	0.000304	0.00138	CcSEcCtD
Amantadine—Headache—Azathioprine—multiple sclerosis	0.000303	0.00137	CcSEcCtD
Amantadine—Dry mouth—Triamcinolone—multiple sclerosis	0.000301	0.00136	CcSEcCtD
Amantadine—Angiopathy—Prednisone—multiple sclerosis	0.000297	0.00135	CcSEcCtD
Amantadine—Confusional state—Methylprednisolone—multiple sclerosis	0.000296	0.00134	CcSEcCtD
Amantadine—Oedema—Triamcinolone—multiple sclerosis	0.000295	0.00134	CcSEcCtD
Amantadine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000295	0.00134	CcSEcCtD
Amantadine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000294	0.00133	CcSEcCtD
Amantadine—Arrhythmia—Prednisone—multiple sclerosis	0.000293	0.00133	CcSEcCtD
Amantadine—ABCB1—nervous system—multiple sclerosis	0.00029	0.00175	CbGeAlD
Amantadine—Insomnia—Prednisolone—multiple sclerosis	0.00029	0.00131	CcSEcCtD
Amantadine—Alopecia—Prednisone—multiple sclerosis	0.00029	0.00131	CcSEcCtD
Amantadine—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000288	0.00131	CcSEcCtD
Amantadine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000288	0.00131	CcSEcCtD
Amantadine—Paraesthesia—Prednisolone—multiple sclerosis	0.000288	0.00131	CcSEcCtD
Amantadine—Tachycardia—Triamcinolone—multiple sclerosis	0.000288	0.0013	CcSEcCtD
Amantadine—Mental disorder—Prednisone—multiple sclerosis	0.000287	0.0013	CcSEcCtD
Amantadine—Nausea—Azathioprine—multiple sclerosis	0.000287	0.0013	CcSEcCtD
Amantadine—Tachycardia—Methylprednisolone—multiple sclerosis	0.000287	0.0013	CcSEcCtD
Amantadine—Skin disorder—Methylprednisolone—multiple sclerosis	0.000286	0.0013	CcSEcCtD
Amantadine—Malnutrition—Prednisone—multiple sclerosis	0.000285	0.00129	CcSEcCtD
Amantadine—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000285	0.00129	CcSEcCtD
Amantadine—Agranulocytosis—Methotrexate—multiple sclerosis	0.000285	0.00129	CcSEcCtD
Amantadine—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000284	0.00129	CcSEcCtD
Amantadine—Convulsion—Betamethasone—multiple sclerosis	0.000284	0.00129	CcSEcCtD
Amantadine—Convulsion—Dexamethasone—multiple sclerosis	0.000284	0.00129	CcSEcCtD
Amantadine—Hypertension—Dexamethasone—multiple sclerosis	0.000283	0.00128	CcSEcCtD
Amantadine—Hypertension—Betamethasone—multiple sclerosis	0.000283	0.00128	CcSEcCtD
Amantadine—Asthenia—Mitoxantrone—multiple sclerosis	0.00028	0.00127	CcSEcCtD
Amantadine—ABCB1—central nervous system—multiple sclerosis	0.000279	0.00169	CbGeAlD
Amantadine—Anxiety—Dexamethasone—multiple sclerosis	0.000278	0.00126	CcSEcCtD
Amantadine—Anxiety—Betamethasone—multiple sclerosis	0.000278	0.00126	CcSEcCtD
Amantadine—Hypotension—Methylprednisolone—multiple sclerosis	0.000275	0.00125	CcSEcCtD
Amantadine—ABCB1—cerebellum—multiple sclerosis	0.000273	0.00165	CbGeAlD
Amantadine—Urinary tract disorder—Methotrexate—multiple sclerosis	0.000271	0.00123	CcSEcCtD
Amantadine—Vision blurred—Prednisone—multiple sclerosis	0.000269	0.00122	CcSEcCtD
Amantadine—Urethral disorder—Methotrexate—multiple sclerosis	0.000269	0.00122	CcSEcCtD
Amantadine—Oedema—Dexamethasone—multiple sclerosis	0.000267	0.00121	CcSEcCtD
Amantadine—Oedema—Betamethasone—multiple sclerosis	0.000267	0.00121	CcSEcCtD
Amantadine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000267	0.00121	CcSEcCtD
Amantadine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000267	0.00121	CcSEcCtD
Amantadine—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000267	0.00121	CcSEcCtD
Amantadine—Insomnia—Triamcinolone—multiple sclerosis	0.000267	0.00121	CcSEcCtD
Amantadine—Insomnia—Methylprednisolone—multiple sclerosis	0.000266	0.00121	CcSEcCtD
Amantadine—Paraesthesia—Triamcinolone—multiple sclerosis	0.000265	0.0012	CcSEcCtD
Amantadine—Feeling abnormal—Prednisolone—multiple sclerosis	0.000264	0.0012	CcSEcCtD
Amantadine—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000264	0.0012	CcSEcCtD
Amantadine—Visual impairment—Methotrexate—multiple sclerosis	0.000264	0.0012	CcSEcCtD
Amantadine—Dyspnoea—Triamcinolone—multiple sclerosis	0.000263	0.00119	CcSEcCtD
Amantadine—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000262	0.00119	CcSEcCtD
Amantadine—Nervous system disorder—Betamethasone—multiple sclerosis	0.000262	0.00119	CcSEcCtD
Amantadine—Agitation—Prednisone—multiple sclerosis	0.000262	0.00119	CcSEcCtD
Amantadine—Tachycardia—Dexamethasone—multiple sclerosis	0.000261	0.00118	CcSEcCtD
Amantadine—Tachycardia—Betamethasone—multiple sclerosis	0.000261	0.00118	CcSEcCtD
Amantadine—Dyspepsia—Triamcinolone—multiple sclerosis	0.000259	0.00118	CcSEcCtD
Amantadine—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000259	0.00117	CcSEcCtD
Amantadine—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000258	0.00117	CcSEcCtD
Amantadine—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000258	0.00117	CcSEcCtD
Amantadine—Eye disorder—Methotrexate—multiple sclerosis	0.000256	0.00116	CcSEcCtD
Amantadine—Anorexia—Dexamethasone—multiple sclerosis	0.000255	0.00116	CcSEcCtD
Amantadine—Anorexia—Betamethasone—multiple sclerosis	0.000255	0.00116	CcSEcCtD
Amantadine—Cardiac disorder—Methotrexate—multiple sclerosis	0.000254	0.00115	CcSEcCtD
Amantadine—Fatigue—Triamcinolone—multiple sclerosis	0.000254	0.00115	CcSEcCtD
Amantadine—Fatigue—Methylprednisolone—multiple sclerosis	0.000254	0.00115	CcSEcCtD
Amantadine—Hypotension—Betamethasone—multiple sclerosis	0.00025	0.00113	CcSEcCtD
Amantadine—Hypotension—Dexamethasone—multiple sclerosis	0.00025	0.00113	CcSEcCtD
Amantadine—Angiopathy—Methotrexate—multiple sclerosis	0.000249	0.00113	CcSEcCtD
Amantadine—Vomiting—Mitoxantrone—multiple sclerosis	0.000248	0.00113	CcSEcCtD
Amantadine—Convulsion—Prednisone—multiple sclerosis	0.000247	0.00112	CcSEcCtD
Amantadine—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000247	0.00112	CcSEcCtD
Amantadine—Hypertension—Prednisone—multiple sclerosis	0.000246	0.00112	CcSEcCtD
Amantadine—Rash—Mitoxantrone—multiple sclerosis	0.000246	0.00112	CcSEcCtD
Amantadine—Dermatitis—Mitoxantrone—multiple sclerosis	0.000246	0.00112	CcSEcCtD
Amantadine—Headache—Mitoxantrone—multiple sclerosis	0.000245	0.00111	CcSEcCtD
Amantadine—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000243	0.0011	CcSEcCtD
Amantadine—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000242	0.0011	CcSEcCtD
Amantadine—Anxiety—Prednisone—multiple sclerosis	0.000242	0.0011	CcSEcCtD
Amantadine—Alopecia—Methotrexate—multiple sclerosis	0.000242	0.0011	CcSEcCtD
Amantadine—Insomnia—Betamethasone—multiple sclerosis	0.000242	0.0011	CcSEcCtD
Amantadine—Insomnia—Dexamethasone—multiple sclerosis	0.000242	0.0011	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000241	0.00109	CcSEcCtD
Amantadine—Paraesthesia—Betamethasone—multiple sclerosis	0.00024	0.00109	CcSEcCtD
Amantadine—Paraesthesia—Dexamethasone—multiple sclerosis	0.00024	0.00109	CcSEcCtD
Amantadine—Mental disorder—Methotrexate—multiple sclerosis	0.00024	0.00109	CcSEcCtD
Amantadine—Malnutrition—Methotrexate—multiple sclerosis	0.000238	0.00108	CcSEcCtD
Amantadine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000236	0.00107	CcSEcCtD
Amantadine—Dyspepsia—Dexamethasone—multiple sclerosis	0.000235	0.00107	CcSEcCtD
Amantadine—Dyspepsia—Betamethasone—multiple sclerosis	0.000235	0.00107	CcSEcCtD
Amantadine—Body temperature increased—Triamcinolone—multiple sclerosis	0.000233	0.00106	CcSEcCtD
Amantadine—Oedema—Prednisone—multiple sclerosis	0.000233	0.00106	CcSEcCtD
Amantadine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000233	0.00106	CcSEcCtD
Amantadine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000232	0.00105	CcSEcCtD
Amantadine—Decreased appetite—Betamethasone—multiple sclerosis	0.000232	0.00105	CcSEcCtD
Amantadine—Nausea—Mitoxantrone—multiple sclerosis	0.000232	0.00105	CcSEcCtD
Amantadine—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000231	0.00105	CcSEcCtD
Amantadine—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000231	0.00105	CcSEcCtD
Amantadine—Fatigue—Dexamethasone—multiple sclerosis	0.000231	0.00105	CcSEcCtD
Amantadine—Fatigue—Betamethasone—multiple sclerosis	0.000231	0.00105	CcSEcCtD
Amantadine—Nervous system disorder—Prednisone—multiple sclerosis	0.000228	0.00104	CcSEcCtD
Amantadine—Tachycardia—Prednisone—multiple sclerosis	0.000227	0.00103	CcSEcCtD
Amantadine—Skin disorder—Prednisone—multiple sclerosis	0.000226	0.00103	CcSEcCtD
Amantadine—Hyperhidrosis—Prednisone—multiple sclerosis	0.000225	0.00102	CcSEcCtD
Amantadine—Vision blurred—Methotrexate—multiple sclerosis	0.000225	0.00102	CcSEcCtD
Amantadine—Anorexia—Prednisone—multiple sclerosis	0.000222	0.00101	CcSEcCtD
Amantadine—ABCB1—brain—multiple sclerosis	0.000222	0.00134	CbGeAlD
Amantadine—Feeling abnormal—Betamethasone—multiple sclerosis	0.00022	0.000999	CcSEcCtD
Amantadine—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00022	0.000999	CcSEcCtD
Amantadine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000217	0.000985	CcSEcCtD
Amantadine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000217	0.000983	CcSEcCtD
Amantadine—Leukopenia—Methotrexate—multiple sclerosis	0.000213	0.000968	CcSEcCtD
Amantadine—Dizziness—Prednisolone—multiple sclerosis	0.000212	0.000961	CcSEcCtD
Amantadine—Asthenia—Triamcinolone—multiple sclerosis	0.000211	0.000959	CcSEcCtD
Amantadine—Body temperature increased—Betamethasone—multiple sclerosis	0.000211	0.000959	CcSEcCtD
Amantadine—Body temperature increased—Dexamethasone—multiple sclerosis	0.000211	0.000959	CcSEcCtD
Amantadine—Asthenia—Methylprednisolone—multiple sclerosis	0.000211	0.000957	CcSEcCtD
Amantadine—Insomnia—Prednisone—multiple sclerosis	0.000211	0.000955	CcSEcCtD
Amantadine—Paraesthesia—Prednisone—multiple sclerosis	0.000209	0.000948	CcSEcCtD
Amantadine—Pruritus—Triamcinolone—multiple sclerosis	0.000208	0.000946	CcSEcCtD
Amantadine—Pruritus—Methylprednisolone—multiple sclerosis	0.000208	0.000943	CcSEcCtD
Amantadine—Convulsion—Methotrexate—multiple sclerosis	0.000207	0.000937	CcSEcCtD
Amantadine—Dyspepsia—Prednisone—multiple sclerosis	0.000205	0.00093	CcSEcCtD
Amantadine—Decreased appetite—Prednisone—multiple sclerosis	0.000202	0.000918	CcSEcCtD
Amantadine—Rash—Prednisolone—multiple sclerosis	0.000202	0.000916	CcSEcCtD
Amantadine—Dermatitis—Prednisolone—multiple sclerosis	0.000202	0.000916	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000202	0.000914	CcSEcCtD
Amantadine—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000201	0.000912	CcSEcCtD
Amantadine—Fatigue—Prednisone—multiple sclerosis	0.000201	0.000911	CcSEcCtD
Amantadine—Headache—Prednisolone—multiple sclerosis	0.000201	0.00091	CcSEcCtD
Amantadine—Constipation—Prednisone—multiple sclerosis	0.000199	0.000903	CcSEcCtD
Amantadine—Confusional state—Methotrexate—multiple sclerosis	0.000196	0.00089	CcSEcCtD
Amantadine—Dizziness—Triamcinolone—multiple sclerosis	0.000195	0.000884	CcSEcCtD
Amantadine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000195	0.000883	CcSEcCtD
Amantadine—Dizziness—Methylprednisolone—multiple sclerosis	0.000194	0.000882	CcSEcCtD
Amantadine—Feeling abnormal—Prednisone—multiple sclerosis	0.000192	0.00087	CcSEcCtD
Amantadine—Asthenia—Dexamethasone—multiple sclerosis	0.000192	0.00087	CcSEcCtD
Amantadine—Asthenia—Betamethasone—multiple sclerosis	0.000192	0.00087	CcSEcCtD
Amantadine—Nervous system disorder—Methotrexate—multiple sclerosis	0.000191	0.000866	CcSEcCtD
Amantadine—Nausea—Prednisolone—multiple sclerosis	0.00019	0.000863	CcSEcCtD
Amantadine—Pruritus—Dexamethasone—multiple sclerosis	0.000189	0.000858	CcSEcCtD
Amantadine—Pruritus—Betamethasone—multiple sclerosis	0.000189	0.000858	CcSEcCtD
Amantadine—Skin disorder—Methotrexate—multiple sclerosis	0.000189	0.000857	CcSEcCtD
Amantadine—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000188	0.000853	CcSEcCtD
Amantadine—Vomiting—Triamcinolone—multiple sclerosis	0.000187	0.00085	CcSEcCtD
Amantadine—Vomiting—Methylprednisolone—multiple sclerosis	0.000187	0.000848	CcSEcCtD
Amantadine—Rash—Triamcinolone—multiple sclerosis	0.000186	0.000843	CcSEcCtD
Amantadine—Dermatitis—Triamcinolone—multiple sclerosis	0.000186	0.000842	CcSEcCtD
Amantadine—Anorexia—Methotrexate—multiple sclerosis	0.000186	0.000841	CcSEcCtD
Amantadine—Rash—Methylprednisolone—multiple sclerosis	0.000185	0.000841	CcSEcCtD
Amantadine—Dermatitis—Methylprednisolone—multiple sclerosis	0.000185	0.00084	CcSEcCtD
Amantadine—Headache—Triamcinolone—multiple sclerosis	0.000185	0.000837	CcSEcCtD
Amantadine—Headache—Methylprednisolone—multiple sclerosis	0.000184	0.000835	CcSEcCtD
Amantadine—Body temperature increased—Prednisone—multiple sclerosis	0.000184	0.000835	CcSEcCtD
Amantadine—Diarrhoea—Dexamethasone—multiple sclerosis	0.000183	0.00083	CcSEcCtD
Amantadine—Diarrhoea—Betamethasone—multiple sclerosis	0.000183	0.00083	CcSEcCtD
Amantadine—Hypotension—Methotrexate—multiple sclerosis	0.000182	0.000825	CcSEcCtD
Amantadine—Dizziness—Dexamethasone—multiple sclerosis	0.000177	0.000802	CcSEcCtD
Amantadine—Dizziness—Betamethasone—multiple sclerosis	0.000177	0.000802	CcSEcCtD
Amantadine—Insomnia—Methotrexate—multiple sclerosis	0.000176	0.000798	CcSEcCtD
Amantadine—Nausea—Triamcinolone—multiple sclerosis	0.000175	0.000794	CcSEcCtD
Amantadine—Paraesthesia—Methotrexate—multiple sclerosis	0.000175	0.000793	CcSEcCtD
Amantadine—Nausea—Methylprednisolone—multiple sclerosis	0.000175	0.000792	CcSEcCtD
Amantadine—Dyspnoea—Methotrexate—multiple sclerosis	0.000174	0.000787	CcSEcCtD
Amantadine—Somnolence—Methotrexate—multiple sclerosis	0.000173	0.000785	CcSEcCtD
Amantadine—Hypersensitivity—Prednisone—multiple sclerosis	0.000172	0.000778	CcSEcCtD
Amantadine—Dyspepsia—Methotrexate—multiple sclerosis	0.000171	0.000777	CcSEcCtD
Amantadine—Vomiting—Dexamethasone—multiple sclerosis	0.00017	0.000771	CcSEcCtD
Amantadine—Vomiting—Betamethasone—multiple sclerosis	0.00017	0.000771	CcSEcCtD
Amantadine—Decreased appetite—Methotrexate—multiple sclerosis	0.000169	0.000767	CcSEcCtD
Amantadine—Rash—Betamethasone—multiple sclerosis	0.000169	0.000765	CcSEcCtD
Amantadine—Rash—Dexamethasone—multiple sclerosis	0.000169	0.000765	CcSEcCtD
Amantadine—Dermatitis—Betamethasone—multiple sclerosis	0.000168	0.000764	CcSEcCtD
Amantadine—Dermatitis—Dexamethasone—multiple sclerosis	0.000168	0.000764	CcSEcCtD
Amantadine—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000168	0.000762	CcSEcCtD
Amantadine—Fatigue—Methotrexate—multiple sclerosis	0.000168	0.000761	CcSEcCtD
Amantadine—Headache—Betamethasone—multiple sclerosis	0.000168	0.00076	CcSEcCtD
Amantadine—Headache—Dexamethasone—multiple sclerosis	0.000168	0.00076	CcSEcCtD
Amantadine—Asthenia—Prednisone—multiple sclerosis	0.000167	0.000758	CcSEcCtD
Amantadine—Pruritus—Prednisone—multiple sclerosis	0.000165	0.000747	CcSEcCtD
Amantadine—Feeling abnormal—Methotrexate—multiple sclerosis	0.00016	0.000727	CcSEcCtD
Amantadine—Diarrhoea—Prednisone—multiple sclerosis	0.000159	0.000723	CcSEcCtD
Amantadine—Nausea—Dexamethasone—multiple sclerosis	0.000159	0.00072	CcSEcCtD
Amantadine—Nausea—Betamethasone—multiple sclerosis	0.000159	0.00072	CcSEcCtD
Amantadine—Dizziness—Prednisone—multiple sclerosis	0.000154	0.000698	CcSEcCtD
Amantadine—Body temperature increased—Methotrexate—multiple sclerosis	0.000154	0.000698	CcSEcCtD
Amantadine—Vomiting—Prednisone—multiple sclerosis	0.000148	0.000671	CcSEcCtD
Amantadine—Rash—Prednisone—multiple sclerosis	0.000147	0.000666	CcSEcCtD
Amantadine—Dermatitis—Prednisone—multiple sclerosis	0.000147	0.000665	CcSEcCtD
Amantadine—Headache—Prednisone—multiple sclerosis	0.000146	0.000662	CcSEcCtD
Amantadine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000143	0.00065	CcSEcCtD
Amantadine—Asthenia—Methotrexate—multiple sclerosis	0.00014	0.000633	CcSEcCtD
Amantadine—Nausea—Prednisone—multiple sclerosis	0.000138	0.000627	CcSEcCtD
Amantadine—Pruritus—Methotrexate—multiple sclerosis	0.000138	0.000624	CcSEcCtD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000134	0.00162	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000134	0.00162	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL13—multiple sclerosis	0.000133	0.00161	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR1—multiple sclerosis	0.000133	0.00161	CbGpPWpGaD
Amantadine—Diarrhoea—Methotrexate—multiple sclerosis	0.000133	0.000604	CcSEcCtD
Amantadine—GRIN1—Developmental Biology—PTPRC—multiple sclerosis	0.00013	0.00157	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—HLA-DQA1—multiple sclerosis	0.000129	0.00156	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	0.000129	0.00155	CbGpPWpGaD
Amantadine—Dizziness—Methotrexate—multiple sclerosis	0.000129	0.000584	CcSEcCtD
Amantadine—GRIN2B—Developmental Biology—PTPRC—multiple sclerosis	0.000127	0.00153	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—BCHE—multiple sclerosis	0.000126	0.00153	CbGpPWpGaD
Amantadine—Vomiting—Methotrexate—multiple sclerosis	0.000124	0.000561	CcSEcCtD
Amantadine—DDC—Metabolism—GPC5—multiple sclerosis	0.000123	0.00149	CbGpPWpGaD
Amantadine—Rash—Methotrexate—multiple sclerosis	0.000123	0.000557	CcSEcCtD
Amantadine—Dermatitis—Methotrexate—multiple sclerosis	0.000123	0.000556	CcSEcCtD
Amantadine—GRIN1—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000122	0.00147	CbGpPWpGaD
Amantadine—Headache—Methotrexate—multiple sclerosis	0.000122	0.000553	CcSEcCtD
Amantadine—ABCB1—Allograft Rejection—HLA-DQB1—multiple sclerosis	0.000121	0.00146	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—MYC—multiple sclerosis	0.000119	0.00144	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TGFB1—multiple sclerosis	0.000119	0.00143	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—MAPK1—multiple sclerosis	0.000116	0.0014	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	0.000116	0.0014	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CD86—multiple sclerosis	0.000116	0.0014	CbGpPWpGaD
Amantadine—Nausea—Methotrexate—multiple sclerosis	0.000116	0.000524	CcSEcCtD
Amantadine—GRIN2C—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	0.000115	0.00138	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL10—multiple sclerosis	0.000114	0.00138	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CD40LG—multiple sclerosis	0.000114	0.00138	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP27B1—multiple sclerosis	0.000113	0.00137	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP24A1—multiple sclerosis	0.000113	0.00137	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.000111	0.00134	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—GPR65—multiple sclerosis	0.000111	0.00134	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL4—multiple sclerosis	0.000111	0.00134	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TNF—multiple sclerosis	0.000111	0.00134	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—STAT3—multiple sclerosis	0.000109	0.00132	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—HLA-B—multiple sclerosis	0.000108	0.00131	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CCR2—multiple sclerosis	0.000108	0.0013	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000107	0.00129	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	0.000107	0.00129	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—STAT3—multiple sclerosis	0.000106	0.00128	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	0.000105	0.00126	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—BCHE—multiple sclerosis	0.000104	0.00126	CbGpPWpGaD
Amantadine—MAOB—Metabolism—GPC5—multiple sclerosis	0.000104	0.00125	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—TNF—multiple sclerosis	0.000103	0.00125	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000103	0.00124	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—FAS—multiple sclerosis	0.000102	0.00123	CbGpPWpGaD
Amantadine—DDC—Metabolism—RRM1—multiple sclerosis	0.000102	0.00123	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL2RA—multiple sclerosis	0.000102	0.00123	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CCR1—multiple sclerosis	0.000102	0.00123	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL13—multiple sclerosis	0.000102	0.00123	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	0.000101	0.00123	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—HLA-A—multiple sclerosis	0.0001	0.00121	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.0001	0.00121	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CNR1—multiple sclerosis	9.97e-05	0.0012	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—MAPK1—multiple sclerosis	9.92e-05	0.0012	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MAPK1—multiple sclerosis	9.89e-05	0.00119	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	9.76e-05	0.00118	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—BCHE—multiple sclerosis	9.69e-05	0.00117	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—MAPK1—multiple sclerosis	9.67e-05	0.00117	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	9.5e-05	0.00115	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	9.25e-05	0.00112	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—HLA-DRB1—multiple sclerosis	9.18e-05	0.00111	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	9.14e-05	0.0011	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCL10—multiple sclerosis	8.98e-05	0.00108	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—IL6—multiple sclerosis	8.94e-05	0.00108	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—TNF—multiple sclerosis	8.86e-05	0.00107	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	8.83e-05	0.00107	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—MAPK1—multiple sclerosis	8.78e-05	0.00106	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	8.75e-05	0.00106	CbGpPWpGaD
Amantadine—MAOB—Metabolism—RRM1—multiple sclerosis	8.59e-05	0.00104	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	8.59e-05	0.00104	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SRM—multiple sclerosis	8.54e-05	0.00103	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CD80—multiple sclerosis	8.48e-05	0.00102	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—IL6—multiple sclerosis	8.32e-05	0.001	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—AQP4—multiple sclerosis	8.28e-05	0.000999	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—MAPK1—multiple sclerosis	8.16e-05	0.000985	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—TYK2—multiple sclerosis	8.15e-05	0.000984	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SRM—multiple sclerosis	7.96e-05	0.000961	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—TYK2—multiple sclerosis	7.94e-05	0.000959	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	7.93e-05	0.000957	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—FAS—multiple sclerosis	7.82e-05	0.000944	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—S1PR1—multiple sclerosis	7.78e-05	0.000939	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CCL5—multiple sclerosis	7.73e-05	0.000933	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	7.71e-05	0.000931	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	7.63e-05	0.000921	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	7.55e-05	0.000911	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	7.44e-05	0.000898	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	7.34e-05	0.000886	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	7.32e-05	0.000883	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CCL3—multiple sclerosis	7.23e-05	0.000873	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—IL6—multiple sclerosis	7.15e-05	0.000863	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	7.14e-05	0.000862	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—S1PR1—multiple sclerosis	7.07e-05	0.000853	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—PTGER4—multiple sclerosis	6.96e-05	0.00084	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CCR5—multiple sclerosis	6.96e-05	0.00084	CbGpPWpGaD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—multiple sclerosis	6.82e-05	0.000824	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	6.82e-05	0.000823	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—IL6—multiple sclerosis	6.8e-05	0.00082	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCR3—multiple sclerosis	6.72e-05	0.000812	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—MAPK1—multiple sclerosis	6.7e-05	0.000809	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IFNG—multiple sclerosis	6.7e-05	0.000809	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—RGS1—multiple sclerosis	6.62e-05	0.000799	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CCR2—multiple sclerosis	6.54e-05	0.00079	CbGpPWpGaD
Amantadine—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	6.46e-05	0.00078	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MMP9—multiple sclerosis	6.42e-05	0.000775	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—GPR65—multiple sclerosis	6.27e-05	0.000757	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MMP9—multiple sclerosis	6.26e-05	0.000755	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	6.14e-05	0.000742	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CNR1—multiple sclerosis	6.04e-05	0.000729	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP27B1—multiple sclerosis	6.02e-05	0.000726	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP24A1—multiple sclerosis	6.02e-05	0.000726	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—RGS1—multiple sclerosis	6.01e-05	0.000725	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL1B—multiple sclerosis	5.98e-05	0.000722	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—IL2—multiple sclerosis	5.96e-05	0.000719	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5.89e-05	0.000711	CbGpPWpGaD
Amantadine—DDC—Metabolism—BCHE—multiple sclerosis	5.86e-05	0.000708	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—MAPK1—multiple sclerosis	5.85e-05	0.000706	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TYK2—multiple sclerosis	5.81e-05	0.000702	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CCR1—multiple sclerosis	5.74e-05	0.000692	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL13—multiple sclerosis	5.74e-05	0.000692	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.72e-05	0.000691	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—MAPK1—multiple sclerosis	5.7e-05	0.000688	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—GPR65—multiple sclerosis	5.7e-05	0.000688	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TYK2—multiple sclerosis	5.67e-05	0.000684	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP27B1—multiple sclerosis	5.61e-05	0.000677	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP24A1—multiple sclerosis	5.61e-05	0.000677	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	5.53e-05	0.000668	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—LINGO1—multiple sclerosis	5.51e-05	0.000665	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—GPC5—multiple sclerosis	5.5e-05	0.000664	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—POMC—multiple sclerosis	5.44e-05	0.000657	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL10—multiple sclerosis	5.43e-05	0.000656	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCR1—multiple sclerosis	5.21e-05	0.000629	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL13—multiple sclerosis	5.21e-05	0.000629	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MAPK1—multiple sclerosis	5.19e-05	0.000626	CbGpPWpGaD
Amantadine—SLC22A2—SLC-mediated transmembrane transport—ALB—multiple sclerosis	5.18e-05	0.000626	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—GPC5—multiple sclerosis	5.13e-05	0.000619	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MAPK1—multiple sclerosis	5.06e-05	0.00061	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	5.04e-05	0.000609	CbGpPWpGaD
Amantadine—MAOB—Metabolism—BCHE—multiple sclerosis	4.93e-05	0.000596	CbGpPWpGaD
Amantadine—SLC22A1—SLC-mediated transmembrane transport—ALB—multiple sclerosis	4.83e-05	0.000583	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TAGAP—multiple sclerosis	4.78e-05	0.000576	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CCL5—multiple sclerosis	4.68e-05	0.000565	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SRM—multiple sclerosis	4.66e-05	0.000563	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—TGFB1—multiple sclerosis	4.65e-05	0.000561	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MMP9—multiple sclerosis	4.58e-05	0.000553	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—RRM1—multiple sclerosis	4.56e-05	0.00055	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.52e-05	0.000546	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MMP9—multiple sclerosis	4.46e-05	0.000539	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—TNF—multiple sclerosis	4.34e-05	0.000524	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	4.33e-05	0.000522	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—RRM1—multiple sclerosis	4.25e-05	0.000513	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	4.23e-05	0.000511	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CCR5—multiple sclerosis	4.21e-05	0.000509	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—S1PR1—multiple sclerosis	4.17e-05	0.000504	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—STAT3—multiple sclerosis	4.07e-05	0.000492	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GPC5—multiple sclerosis	4.06e-05	0.00049	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	4e-05	0.000483	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—IL6—multiple sclerosis	3.99e-05	0.000481	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—STAT3—multiple sclerosis	3.97e-05	0.000479	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.97e-05	0.000479	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PTGER4—multiple sclerosis	3.93e-05	0.000475	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—IL6—multiple sclerosis	3.88e-05	0.000469	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCR3—multiple sclerosis	3.8e-05	0.000459	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TGFB1—multiple sclerosis	3.77e-05	0.000456	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCL3—multiple sclerosis	3.71e-05	0.000448	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MAPK1—multiple sclerosis	3.7e-05	0.000447	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—MAPK1—multiple sclerosis	3.7e-05	0.000446	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CCR2—multiple sclerosis	3.7e-05	0.000446	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TGFB1—multiple sclerosis	3.68e-05	0.000444	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MAPK1—multiple sclerosis	3.61e-05	0.000436	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PTGER4—multiple sclerosis	3.57e-05	0.000431	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RGS1—multiple sclerosis	3.55e-05	0.000428	CbGpPWpGaD
Amantadine—DDC—Metabolism—APOE—multiple sclerosis	3.53e-05	0.000426	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—TNF—multiple sclerosis	3.52e-05	0.000425	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCR3—multiple sclerosis	3.45e-05	0.000417	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—TNF—multiple sclerosis	3.44e-05	0.000415	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CNR1—multiple sclerosis	3.41e-05	0.000412	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—GPR65—multiple sclerosis	3.36e-05	0.000406	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCR2—multiple sclerosis	3.36e-05	0.000405	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—POMC—multiple sclerosis	3.29e-05	0.000398	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP24A1—multiple sclerosis	3.29e-05	0.000397	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP27B1—multiple sclerosis	3.29e-05	0.000397	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CCL2—multiple sclerosis	3.22e-05	0.000389	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CNR1—multiple sclerosis	3.1e-05	0.000374	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL13—multiple sclerosis	3.08e-05	0.000371	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCR1—multiple sclerosis	3.08e-05	0.000371	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL10—multiple sclerosis	3.07e-05	0.000371	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—MAPK1—multiple sclerosis	3.04e-05	0.000367	CbGpPWpGaD
Amantadine—DDC—Metabolism—POMC—multiple sclerosis	3.03e-05	0.000366	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—GPC5—multiple sclerosis	3.01e-05	0.000363	CbGpPWpGaD
Amantadine—MAOB—Metabolism—APOE—multiple sclerosis	2.97e-05	0.000358	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—IL6—multiple sclerosis	2.84e-05	0.000343	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—MAPK1—multiple sclerosis	2.83e-05	0.000342	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL10—multiple sclerosis	2.79e-05	0.000337	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—IL6—multiple sclerosis	2.77e-05	0.000335	CbGpPWpGaD
Amantadine—DDC—Metabolism—ALB—multiple sclerosis	2.76e-05	0.000333	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—IL6—multiple sclerosis	2.68e-05	0.000323	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CCL5—multiple sclerosis	2.64e-05	0.000319	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.63e-05	0.000318	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—BCHE—multiple sclerosis	2.62e-05	0.000316	CbGpPWpGaD
Amantadine—MAOB—Metabolism—POMC—multiple sclerosis	2.55e-05	0.000308	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—RRM1—multiple sclerosis	2.49e-05	0.000301	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.46e-05	0.000296	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—BCHE—multiple sclerosis	2.44e-05	0.000295	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCL5—multiple sclerosis	2.4e-05	0.00029	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CCR5—multiple sclerosis	2.38e-05	0.000288	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2RA—multiple sclerosis	2.35e-05	0.000283	CbGpPWpGaD
Amantadine—MAOB—Metabolism—ALB—multiple sclerosis	2.32e-05	0.000281	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.3e-05	0.000277	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.29e-05	0.000277	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.25e-05	0.000271	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL3—multiple sclerosis	2.19e-05	0.000265	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCR5—multiple sclerosis	2.16e-05	0.000261	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.14e-05	0.000258	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2RA—multiple sclerosis	2.13e-05	0.000257	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTGER4—multiple sclerosis	2.11e-05	0.000255	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PGR—multiple sclerosis	2.08e-05	0.000251	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCR3—multiple sclerosis	2.04e-05	0.000246	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD28—multiple sclerosis	2.02e-05	0.000244	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCR2—multiple sclerosis	1.98e-05	0.000239	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—POMC—multiple sclerosis	1.86e-05	0.000225	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CNR1—multiple sclerosis	1.83e-05	0.000221	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—POMC—multiple sclerosis	1.69e-05	0.000204	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCL2—multiple sclerosis	1.65e-05	0.0002	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL10—multiple sclerosis	1.65e-05	0.000199	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—APOE—multiple sclerosis	1.58e-05	0.00019	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—TYK2—multiple sclerosis	1.5e-05	0.000181	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—APOE—multiple sclerosis	1.47e-05	0.000177	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD86—multiple sclerosis	1.44e-05	0.000174	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.44e-05	0.000174	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—BCHE—multiple sclerosis	1.43e-05	0.000173	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL5—multiple sclerosis	1.42e-05	0.000171	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	1.38e-05	0.000166	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—POMC—multiple sclerosis	1.35e-05	0.000163	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SPP1—multiple sclerosis	1.31e-05	0.000159	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCR5—multiple sclerosis	1.28e-05	0.000154	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—POMC—multiple sclerosis	1.26e-05	0.000152	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	1.26e-05	0.000152	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL2—multiple sclerosis	1.25e-05	0.000151	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—ALB—multiple sclerosis	1.23e-05	0.000149	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—APOE—multiple sclerosis	1.16e-05	0.00014	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—ALB—multiple sclerosis	1.15e-05	0.000139	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CD80—multiple sclerosis	1.05e-05	0.000127	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—POMC—multiple sclerosis	9.99e-06	0.000121	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL2—multiple sclerosis	9.77e-06	0.000118	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	9.56e-06	0.000115	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TYK2—multiple sclerosis	8.87e-06	0.000107	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—APOE—multiple sclerosis	8.61e-06	0.000104	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—POMC—multiple sclerosis	7.39e-06	8.92e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL2—multiple sclerosis	7.38e-06	8.91e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—IL6—multiple sclerosis	7.35e-06	8.87e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MMP9—multiple sclerosis	6.99e-06	8.43e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—ALB—multiple sclerosis	6.74e-06	8.14e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STAT3—multiple sclerosis	6.21e-06	7.5e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MYC—multiple sclerosis	5.77e-06	6.97e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	5.76e-06	6.95e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	5.65e-06	6.82e-05	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IL6—multiple sclerosis	4.34e-06	5.24e-05	CbGpPWpGaD
